If you have been reading about IGF-1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Historians Robert Friedel and Paul Israel list inventors of incandescent lamps prior to Joseph Swan and Thomas Edison of General Electric. They conclude that Edison's version was the first practical implementation, able to outstrip the others because of a combination of four factors: an effective incandescent material; a vacuum higher than other implementations; a high resistance that made power distribution from a centralized source economically viable, and the development of the associated components required for a large-scale lighting system. However, Joseph Swan's incandescent light bulb pre-dated Edison's and was sufficiently practical that it was actually installed and in daily use in London in 1881. Historian Thomas Hughes has attributed Edison's business success to his development of an entire, integrated system of electric lighting.
==== Enantiomeric excesses observed in extraterrestrial amino acids ==== More recently, amino acids from several carbonaceous chondrites have been identified with significant L-enantiomeric excesses. L-excesses from 3–15% in several non-protein α-dialkyl amino acids have been found in the Murchison and Murray meteorites. Their extraterrestrial origin is indicated by their absence in biological systems and significant heavy isotope enrichments in 13C and deuterium compared to terrestrial values. Further characterisation of L-isovaline excesses up to 20.5% in a range of carbonaceous chondrite groups have supported a hypothesis that increasing hydrothermal alteration of the host meteorite correlates with increasing observed L-enantiomeric excess. Large L-excesses for α-H amino acids have also been reported, but these are more problematic due to the potential for terrestrial contamination. The ungrouped C2 chondrite Tagish Lake has L-aspartic acid excesses up to ~60%, with carbon isotope measurements indicating an extraterrestrial origin due to significant enrichments in 13C. In Tagish Lake, proteinogenic amino acids show both significant L-excesses, and racemic mixtures: glutamic acid, serine, and threonine were found to have ~50 – 99% L-excesses, while alanine was racemic. It has been proposed that extraterrestrial amino acid L-excesses observed in carbonaceous chondrites are a result of differences in the crystallisation behaviour of the enantiomers.
"A Fighter From the Ground Up." Popular Science, July 1943, one of earliest detailed articles on P-51A Archived 23 October 2013 at the Wayback Machine "Wild Horses of the Sky," Popular Mechanics, November 1943 Joe Baugher, North American P-51 Mustang Archived 23 July 2011 at the Wayback Machine Camouflage and Markings of P-51 Mustang Parts 1–4 USAAF plus Allison engine versions RAF and Commonwealth Archived 1 March 2012 at the Wayback Machine Allison-powered Mustang performance test reports; 1940, 1942, 1943, 1944 Archived 22 December 2008 at the Wayback Machine P-51B Mustang performance test report, May 1943 Archived 9 January 2008 at the Wayback Machine P-51 combat reports Archived 23 December 2007 at the Wayback Machine NACA-WR-L-566 "Flying qualities and stalling characteristics of North American XP-51 airplane", April 1943. (PDF) North American P-51 profile, photos and technical details for each mk "Flight Characteristics of the North American P-51 Mustang: How to Fly the P-51 Mustang" on YouTube "Mustang Squadron" a 1942 Flight article "Army Co-Op Mustang" a 1942 Flight article "Unobtrusive Cleverness" a 1942 Flight article "Long Range Mustang" a 1944 Flight article P-51 in Flight Over California (1942) Flight manual Mustang P-51A Archived 15 May 2024 at the Wayback Machine – The Museum of Flight Digital Collections Pilot training manual for the Mustang P-51 Archived 8 October 2024 at the Wayback Machine – The Museum of Flight Digital Collections
The third phase, PSI:Biology, began in 2010 and consisted of networks of investigators applying high-throughput structure determination to study a broad range of biological and biomedical problems. PSI program ended on 7/1/2015, even that some of the PSI centers continue structure determination supported by other funding mechanisms.
Sources: en.wikipedia.org
Curd products vary by region and include cottage cheese, curd cheese (both curdled by bacteria and sometimes also rennet), farmer cheese, pot cheese, queso blanco, and paneer. The word can also refer to a non-dairy substance of similar appearance or consistency, though in these cases a modifier or the word 'curdled' is generally used. In Hungary a form of curds called túró is an ingredient in several national dishes, such as túrós palacsinta, túrós csusza and túrógombóc. In 2019, rögös túró—a form that has a unique texture "consisting of clumps of loose lumps reminiscent of cauliflower" (the name translates to "lumpy túró")—was granted the status of Traditional Speciality Guaranteed (TSG) by the EU. In Turkey, curds are called keş and are served on fried bread and are also eaten with macaroni in the provinces of Bolu and Zonguldak. In Sri Lanka, curd is eaten fresh as a dessert since antiquity. Usually buffalo curd cured in clay pots and served with kitul treacle (Caryota urens), is considered a delicacy in almost every part of the island. Although cows milk curd also is produced, Buffalo curd is the preferred variety. In Nepal, curd is produced by souring pasteurized milk with natural micro-flora. The pasteurized milk is added to a container called theki carved out of wood like Daar(Boehmeria Rugulosa). The milk is left for 12–16 hours and the micro-organisms entrapped within the Theki act as inocula. The curd produced after is used to make chhurpi and variations of it. Albanian gjiza is made by boiling whey for about 15 minutes and adding vinegar or lemon.
Anthropomorphised ants have often been used in fables, children's stories, and religious texts to represent industriousness and cooperative effort, such as in the Aesop fable The Ant and the Grasshopper. In the Quran, Sulayman is said to have heard and understood an ant warning other ants to return home to avoid being accidentally crushed by Sulayman and his marching army.[Quran 27:18], In parts of Africa, ants are considered to be the messengers of the deities. Some Native American mythology, such as the Hopi mythology, considers ants as the first animals. Ant bites are often said to have curative properties. The sting of some species of Pseudomyrmex is claimed to give fever relief. Ant bites are used in the initiation ceremonies of some Amazon Indian cultures as a test of endurance. In Greek mythology, the goddess Athena turned the maiden Myrmex into an ant when the latter claimed to have invented the plough, when in fact it was Athena's own invention.
=== Compilation appearances === 2013: Women Who Kill (Tracks 1–3) (Entertainment One) – DVD/download/streaming 2015: Comedy Central Stand-Up Vault# 3 (Comedy Central) – DVD 2018: Just for Laughs: The Nasty Show, Vol. 1 (Tracks 1–2) – CD/download/streaming 2018: Just for Laughs: The Nasty Show, Vol. 2 (Tracks 1–3) – CD/download/streaming 2019: Just for Laughs: Funny AF, Vol. 1 (Track 1) – CD/download/streaming 2019: Just for Laughs: Funny AF, Vol. 2 (Tracks 1–3) – CD/download/streaming 2019: Just for Laughs: Funny AF, Vol. 3 (Track 1) – CD/download/streaming
Sources: en.wikipedia.org
Gearbox Software, L.L.C. is an American video game development company based in Frisco, Texas. It was established as a limited liability company in February 1999 by five developers formerly of Rebel Boat Rocker. Randy Pitchford, one of the founders, serves as president and chief executive officer. Gearbox initially created expansions for the Valve game Half-Life, then ported that game and others to console platforms. In 2005, Gearbox launched its first independent set of games, Brothers in Arms, on console and mobile devices. It became its flagship franchise and spun off a comic book series, television documentary, books, and action figures. Their second original game series, Borderlands, commenced in 2009, and by 2015 had sold over 26 million copies. The company also owns the intellectual property of Duke Nukem and Homeworld. Gearbox expanded into publishing with the creation of Gearbox Publishing in 2015. A parent company, The Gearbox Entertainment Company, was established for Gearbox Software and Gearbox Publishing in 2019. Gearbox Entertainment was acquired by the Embracer Group in April 2021, becoming its seventh major label. A third division, Gearbox Studios, focusing on television and film productions, was established in October 2021. Due to major restructuring following a failed investment, Embracer announced plans to divest Gearbox to Take-Two Interactive, who had previously published several of Gearbox's games under its 2K label, in March 2024. Take-Two Interactive closed the Gearbox Software acquisition on June 12, 2024.
The epoxy cycle of ethylene oxide is an almost regular triangle with bond angles of about 60° and a significant angular strain corresponding to the energy of 105 kJ/mol. For comparison, in alcohols the C–O–H angle is about 110°; in ethers, the C–O–C angle is 120°. The moment of inertia about each of the principal axes are IA = 32.921×10−40 g·cm2, IB = 37.926×10−40 g·cm2 and IC = 59.510×10−40 g·cm2. The relative instability of the carbon-oxygen bonds in the molecule is revealed by the comparison in the table of the energy required to break two C–O bonds in the ethylene oxide or one C–O bond in ethanol and dimethyl ether:
While for many nutrients, the US Department of Agriculture uses food composition data combined with food consumption survey results to estimate average consumption, the surveys and reports do not include pantothenic acid in the analyses. Less formal estimates of adult daily intakes report about 4 to 7 mg/day. The European Food Safety Authority (EFSA) refers to the collective set of information as Dietary Reference Values, with Population Reference Intake (PRI) instead of RDA, and Average Requirement instead of EAR. AI and UL are defined the same as in the US. For women and men over age 11, the Adequate Intake (AI) is set at 5 mg/day. AI for pregnancy is 5 mg/day, for lactation 7 mg/day. For children ages 1–10 years, the AI is 4 mg/day. These AIs are similar to the US AIs.
=== Prescreening === A significant number of countries maintain prescreening facilities for passengers departing from other jurisdictions to clear border controls before arrival, thereby skipping checkpoints upon arrival. Aside from simplifying arrival formalities, this enables border control authorities to deny entry to potentially inadmissible travellers before they embark and to reduce congestion at border checkpoints at ports of arrival.
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.